CV Overview

CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.

Wall Street analysts forecast CV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CV is10.50 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CapsoVision Inc revenue for the last quarter amounts to 3.92M USD, increased 13.50

CapsoVision Inc. EPS for the last quarter amounts to -0.16 USD, increased 60.00

CapsoVision Inc (CV) has 28 emplpoyees as of March 31 2026.

Today CV has the market capitalization of 356.84M USD.